Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Cyramza® (ramucirumab): Density, pH and other physical and chemical properties
The density of Cyramza is 1.006 g/mL at 20°C (68°F). Further relevant physical and chemical characteristics are listed below.
Physical and chemical characteristics of Cyramza
Appearance: Clear to slightly opalescent and colorless to slightly yellow liquid without visible particles.1
Density: 1.006 g/mL at 20°C (68°F).1
Odor: CYRAMZA does not have any characteristic or distinctive odour.1
Osmolality / Tonicity: 285 mmol/kg (Range 250-320 mmol/kg).1
pH: 6 (Range: 5.7-6.3).1
pI (Isoelectric Point): The isoelectric point of ramucirumab is 8.6 to 9.4.1
Photostability: Like other proteins, the ramucirumab drug product is expected to undergo modifications under extreme light exposure conditions. Exposure to ambient light during dose preparation and administration does not adversely affect the drug product.1
Specific Gravity: 1.006 (no units).1
Viscosity: 1.02cp at room temperature (25°C).1
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: 21 March 2022